When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off ...

Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...

Amid a bullish backdrop for the broader market, Tempus AI (NASDAQ: TEM) stock is posting big gains Wednesday. The company's ...

BTIG analyst Mark Massaro has initiated coverage on Tempus AI (TEM), with a Buy rating and a price target of $60, implying 48 ...

Tempus AI announced a collaboration with AstraZeneca and Pathos AI. The deal will generate $200 million for Tempus AI in data ...

Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with ...

Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

Tempus stands to earn $200 million in data licensing and model development fees from the collaborations, the release said.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $63.78, ...

Tempus AI (TEM) has seen a significant surge on Wednesday, with its stock climbing 14.62% in just one day. The significant boost in TEM stock ...

Tempus AI has reported impressive growth, but some of the volatile quarterly numbers have chased off aggressive investors.